← 產業報告目錄
NAMPT Inhibitor Market Size, Share & Trends Analysis By Molecule Type (Small Molecules, Biologics), By Line of Treatment (1st Line, 2nd Line), By Indication (Acute Respiratory Distress Syndrome, Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma), By Route of Administration (Oral, Intravenous), By Therapeutic Area (Respiratory Disorders, Oncological), by Region, And by Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-28頁數 160報告編號 INSIGHTACE-7117aa735f
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Across the 2025 to 2034 projection horizon, the worldwide NAMPT Inhibitor Market is poised to register a CAGR of 10.9%.
NAMPT Inhibitor covers a pharmaceutical agent that interferes with the function of the nampt enzyme, essential for the synthesis of nad+ (nicotinamide adenine di. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
The market's upward path is bolstered by mounting healthcare spending, technological evolution, and the mounting focus on personalized and precision-based approaches in healthcare.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region poised to deliver the strongest growth trajectory through the forecast period, bolstered by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global NAMPT Inhibitor Market Snapshot
Chapter 4. Global NAMPT Inhibitor Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global NAMPT Inhibitor Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on NAMPT INHIBITOR MARKET Industry Trends
Chapter 5. NAMPT Inhibitor Market Segmentation 1: By Molecule, Estimates & Trend Analysis
5.1. Market Share by Molecule, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Molecule:
5.2.1. Small Molecules
5.2.2. Biologics
Chapter 6. NAMPT Inhibitor Market Segmentation 2: By Therapeutic Area, Estimates & Trend Analysis
6.1. Market Share by Therapeutic Area, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapeutic Area:
6.2.1. Oncological
6.2.2. Respiratory Disorders
Chapter 7. NAMPT Inhibitor Market Segmentation 3: By Indication, Estimates & Trend Analysis
7.1. Market Share by Indication, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
7.2.1. Non-Hodgkin Lymphoma
7.2.2. Hodgkin Lymphoma
7.2.3. Acute Respiratory Distress Syndrome
7.2.4. Acute Myeloid Leukemia
Chapter 8. NAMPT Inhibitor Market Segmentation 4: By Route of Administration, Estimates & Trend Analysis
8.1. Market Share by Route of Administration, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
8.2.1. Oral
8.2.2. Intravenous
Chapter 9. NAMPT Inhibitor Market Segmentation 5: By Line of Treatment, Estimates & Trend Analysis
9.1. Market Share by Line of Treatment, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Line of Treatment:
9.2.1. 1st Line
9.2.2. 2nd Line
Chapter 10. NAMPT Inhibitor Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global NAMPT Inhibitor Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Molecule, 2021-2034
10.2.3. North America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.2.4. North America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.2.5. North America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
10.2.6. North America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Line of Treatment, 2021-2034
10.3. Europe
10.3.1. Europe NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Molecule, 2021-2034
10.3.3. Europe NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.3.4. Europe NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.3.5. Europe NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
10.3.6. Europe NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Line of Treatment, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Molecule, 2021-2034
10.4.3. Asia Pacific NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.4.4. Asia Pacific NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.4.5. Asia Pacific NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2021-2034
10.4.6. Asia Pacific NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Line of Treatment, 2021-2034
10.5. Latin America
10.5.1. Latin America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Molecule, 2021-2034
10.5.3. Latin America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.5.4. Latin America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.5.5. Latin America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
10.5.6. Latin America NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Line of Treatment, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Molecule, 2021-2034
10.6.3. Middle East & Africa NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.6.4. Middle East & Africa NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.6.5. Middle East & Africa NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
10.6.6. Middle East & Africa NAMPT Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Line of Treatment, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Antengene Therapeutics
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Aqualung Therapeutics
11.2.3. Karyopharm Therapeutics
11.2.4. OncoTartis
11.2.5. Onxeo
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們